Blucrab Pharma Private Limited - Due diligence report

A 360° intelligence report on Blucrab Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2016-05-02 Vastral, Gujarat Active Unlisted Active Compliant
Share
BP Blucrab Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Blucrab Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Blucrab Pharma Private Limited is assessed as Low Risk with a Trust Score of 92/100. Blucrab Pharma Private Limited is an active private limited indian non-government company incorporated in 2016, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 23 Jul 2026 from the latest processed filings. Blucrab Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
Meenakshi Yadav 01234567 Director 01/04/2018 6 yrs Approved
AMIT KUMAR TRIPATHI 01234567 Director 01/04/2018 6 yrs Approved
RUBY TRIPATHI 01234567 Director 01/04/2018 6 yrs Approved
RAMA SHANKAR YADAV 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 2 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Operating for 10+ years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 10 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
15 May 2024
Director ceased
Markanday Narayan Panday
Director ceased
Abhishek Kumar Pandey
30 Sep 2023
Director appointed
Meenakshi Yadav (Director)
14 Mar 2019
Director appointed
AMIT KUMAR TRIPATHI (Additional Director)
07 May 2016
Director ceased
SHARIK KHAN
02 May 2016
Incorporated
Registered with Roc Ahmedabad
Director appointed
RUBY TRIPATHI (Director)
Director appointed
RAMA SHANKAR YADAV (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Zodovit Ceramics Private Limited U51495WB2019PTC232307 Burdwan, West Bengal, India
Rhine Exports Private Limited U51506MH2003PTC139833 Navi Mumbai, Maharashtra, India
E And A Components Private Limited U51909TN2014PTC095085 Chennai, Tamil Nadu, India
Ordnc 2024 000031 U25201Rj1999Ptc015404 Private Limited U25201RJ1999PTC015404 Rajasthan., Rajasthan, India
Funex Technologies Private Limited U50400DL2020PTC360774 Jahangir Puri, Delhi, India
Himjoli Products Private Limited U74900UR2009PTC032843 Nainital, Uttarakhand, India
Gulshan Vinimay Private Limited U51909WB2011PTC157876 Kolkata, West Bengal, India
Abachem Specialty Chemicals U24110TN2012PTC086449 Chennai, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Blucrab Pharma Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Blucrab Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Blucrab Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Blucrab Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Blucrab Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Blucrab Pharma Private Limited an active company?

Blucrab Pharma Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Blucrab Pharma Private Limited financially healthy?

Blucrab Pharma Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Blucrab Pharma Private Limited?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Blucrab Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Blucrab Pharma Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Blucrab Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Blucrab Pharma Private Limited?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.